A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells
Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Thomas Olin(Kancera (Sweden)), Jeanette Lundin(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Parviz Kokhaei(Arak University of Medical Sciences), Marzia Palma(Karolinska University Hospital), Björn E. Wahlin(Karolinska University Hospital), Tom A. Mulder(Karolinska University Hospital), Johan Schultz(Kancera (Sweden)), Wen Zhong(Karolinska University Hospital), Ann Svensson(University West)
Cited by 1
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312